C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 76 filers reported holding C4 THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,897,329 | -32.1% | 2,095,338 | +0.4% | 0.00% | – |
| Q2 2023 | $5,738,049 | -50.6% | 2,086,563 | -43.6% | 0.00% | – |
| Q1 2023 | $11,607,771 | -45.7% | 3,696,742 | +2.1% | 0.00% | -100.0% |
| Q4 2022 | $21,364,685 | -29.7% | 3,621,133 | +4.5% | 0.00% | 0.0% |
| Q3 2022 | $30,383,000 | +18.6% | 3,464,572 | +2.0% | 0.00% | 0.0% |
| Q2 2022 | $25,618,000 | -66.4% | 3,397,598 | +8.2% | 0.00% | -50.0% |
| Q1 2022 | $76,177,000 | -30.5% | 3,139,990 | -7.8% | 0.00% | -33.3% |
| Q4 2021 | $109,672,000 | -22.3% | 3,405,982 | +7.9% | 0.00% | -25.0% |
| Q3 2021 | $141,064,000 | +41.6% | 3,157,207 | +19.9% | 0.00% | +33.3% |
| Q2 2021 | $99,610,000 | +125.4% | 2,632,424 | +120.4% | 0.00% | +200.0% |
| Q1 2021 | $44,184,000 | +17.0% | 1,194,492 | +4.8% | 0.00% | 0.0% |
| Q4 2020 | $37,754,000 | – | 1,139,591 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 481,094 | $15,939,000 | 8.67% |
| Bain Capital Life Sciences Investors, LLC | 1,642,209 | $54,406,000 | 3.42% |
| Darwin Global Management, Ltd. | 228,595 | $7,573,000 | 2.11% |
| Asymmetry Capital Management, L.P. | 139,343 | $4,616,000 | 2.10% |
| Cormorant Asset Management, LP | 2,490,065 | $80,021,000 | 1.90% |
| Logos Global Management LP | 477,928 | $15,834,000 | 1.36% |
| SPHERA FUNDS MANAGEMENT LTD. | 443,824 | $14,601,000 | 1.30% |
| Soleus Capital Management, L.P. | 268,548 | $8,897,000 | 1.17% |
| P.A.W. CAPITAL CORP | 40,000 | $1,325,000 | 1.17% |
| RTW INVESTMENTS, LP | 2,149,228 | $68,679,000 | 1.15% |